SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing

PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month t

PMN

Related stories